We are live on
!
Find out more
LBA
Letko, Brosseau & Associates Portfolio holdings
AUM
$6.2B
1-Year Est. Return
38.92%
This Fund
S&P 500
This Quarter
Est. Return
-1.47%
1 Year Est. Return
+38.92%
3 Year Est. Return
+73.78%
5 Year Est. Return
+108.79%
10 Year Est. Return
+305.85%
AUM
$11.4B
AUM Growth
-$318M
(-2.7%)
Cap. Flow
+$3.49M
Cap. Flow
% of AUM
0.03%
Top 10 Holdings %
Top 10 Hldgs %
29.99%
Holding
100
New
2
Increased
15
Reduced
62
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$61.8M |
| 2 |
GSK
GSK
|
+$48.1M |
| 3 |
Teck Resources
TECK
|
+$21.6M |
| 4 |
AVNS
Avanos Medical
AVNS
|
+$6.39M |
| 5 |
Cenovus Energy
CVE
|
+$4.92M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$37M |
| 2 |
TLM
TALISMAN ENERGY INC
TLM
|
+$12.4M |
| 3 |
Kimberly-Clark
KMB
|
+$10.3M |
| 4 |
Thomson Reuters
TRI
|
+$8.19M |
| 5 |
Sun Life Financial
SLF
|
+$6.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 22.78% |
| 2 | Energy | 19.58% |
| 3 | Communication Services | 12.9% |
| 4 | Technology | 8.07% |
| 5 | Industrials | 7.63% |
Similar funds
NP
WIA
EIP
B
CA
ACM
AWA
DTC
Letko, Brosseau & Associates's Q4 2014 Portfolio in Review
As of Q4 2014, Letko, Brosseau & Associates held 100 positions worth $11.4B, down 2.7% from $11.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Trading was light in Q4 2014: portfolio turnover was 4%. Letko, Brosseau & Associates opened 2 new positions and exited 2, leaving the 100-position portfolio largely intact.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 22% a quarter earlier, followed by Energy and Communication Services.
- Letko, Brosseau & Associates's largest Q4 2014 buy was Avanos Medical: 162,551 shares worth $7.39M.
- Letko, Brosseau & Associates added most to Gilead Sciences in Q4 2014, an estimated $61.8M increase.
- Letko, Brosseau & Associates's biggest Q4 2014 reduction was TALISMAN ENERGY INC, cutting an estimated $12.4M.
- Letko, Brosseau & Associates fully exited AstraZeneca in Q4 2014, selling an estimated $37M.
- Letko, Brosseau & Associates's ten largest holdings make up 30% of its $11.4B portfolio in Q4 2014.
- Letko, Brosseau & Associates opened 2 new positions and closed 2 in Q4 2014.
- Letko, Brosseau & Associates's portfolio value fell 2.7% quarter-over-quarter to $11.4B.
Based on Letko, Brosseau & Associates's 13F filing for Q4 2014, filed 10 Feb 2015.